The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Preliminary safety, product parameters, and immune response assessments from a phase II randomized, open-label trial of DN24-02, an autologous cellular immunotherapy (ACI), in patients (pts) with surgically resected HER2+ urothelial cancer (UC) at high risk for recurrence.
Dean F. Bajorin
Consultant or Advisory Role - Dendreon; Lilly; Pfizer
Honoraria - Lilly
Research Funding - Amgen; Dendreon; Genentech; Novartis; Pfizer
Padmanee Sharma
Consultant or Advisory Role - Bristol-Myers Squibb; Dendreon; Helsinn Therapeutics; Jounce Therapeutics; MedImmune
Seth P. Lerner
Consultant or Advisory Role - Dendreon (U)
Robert Brownell Sims
Employment or Leadership Position - Dendreon
Stock Ownership - Dendreon
Amanda Sanders
Employment or Leadership Position - Dendreon
Stock Ownership - Dendreon
Todd DeVries
Employment or Leadership Position - Dendreon
Stock Ownership - Dendreon
Nadeem A. Sheikh
Employment or Leadership Position - Dendreon
Stock Ownership - Dendreon
Leonard G. Gomella
Consultant or Advisory Role - Dendreon
Honoraria - Dendreon
Research Funding - Dendreon